IJCRR - 6(9), May, 2014
Pages: 41-57
PHOSPHORUS-31 MR SPECTROSCOPY OF THE HUMAN BRAIN : TECHNICAL ASPECTS AND BIOMEDICAL APPLICATIONS
Author: Celi S. Andrade, Maria C. G. Otaduy, Eun J. Park, Claudia C. Leite
Category: Healthcare
[Download PDF]
Abstract:
Phosphorus-31 magnetic resonance spectroscopy (31P-MRS) is a non-invasive method that provides useful information about metabolism and phosphoenergetic status in both physiologic and pathologic conditions of the human brain. With the progressive advances in magnetic resonance imaging (MRI) technology, particularly with higher magnetic field strengths, 31P-MRS has been more easily implemented and more readily available in the past few years, which has increasingly extended its access and favored its use in different research fields. However, the current knowledge about this advanced neuroimaging modality is still scarce and fragmented in the literature. Hence, in order to contribute to future researches and to shorten the gap between neuroscientific studies and common clinical routines, we present a comprehensive review about the basic technical aspects and biomedical applications of 31P-MRS.v
Keywords: 31P-MRS, MRI, phosphorus spectroscopy, magnetic resonance imaging, neurometabolism, energetics, phospholipids, pH, magnesium, cell membrane
Citation:
Celi S. Andrade, Maria C. G. Otaduy, Eun J. Park, Claudia C. Leite. PHOSPHORUS-31 MR SPECTROSCOPY OF THE HUMAN BRAIN : TECHNICAL ASPECTS AND BIOMEDICAL APPLICATIONS International Journal of Current Research and Review. 6(9), May, 41-57
References:
REFERENCES
1. Viondury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. 1994 What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol;241(6):354-371.
2. Xu V, Chan H, Lin AP, Sailasuta N, Valencerina S, Tran T, Hovener J, Ross BD. 2008 MR Spectroscopy in Diagnosis and Neurological Decision-Making. Semin Neurol;28(4):407-422.
3. Lei H, Zhu XH, Zhang XL, Qiao HY, Ugurbil K, Chen W. 2003 P-31-P-31 coupling and ATP T-2 measurement in human brain at 7T. Magn Reson Med;50(3):656-658.
4. Jensen JE, Drost DJ, Menon RS, Williamson PC. 2002 In vivo brain P-31-MRS: measuring the phospholipid resonances at 4 Tesla from small voxels. NMR Biomed;15(5):338-347.
5. Qiao HY, Zhang XL, Zhu XH, Du F, Chen W. 2006 In vivo P-31 MRS of human brain at high/ultrahigh fields: a quantitative comparison of NMR detection sensitivity and spectral resolution between 4 T and 7 T. Magn Reson Imaging;24(10):1281-1286.
6. Castillo M, Kwock L, Mukherji SK. 1996 Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol;17(1):1-15.
7. Kwock L. 1998 Localized MR spectroscopy - Basic principles. Neuroimaging Clin N Am;8(4):713-+.
8. Christensen JD, Yurgelun-Todd DA, Babb SM, Gruber SA, Cohen BM, Renshaw PF. 1999 Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy. Brain Res;834(1-2):1-5.
9. Ross B, Lin A, Harris K, Bhattacharya P, Schweinsburg B. 2003 Clinical experience with C-13 MRS in vivo. NMR Biomed;16(6- 7):358-369.
10. Forester BP, Streeter CC, Berlow YA, Tian H, Wardrop M, Finn CT, Harper D, Renshaw PF, Moore CM. 2009 Brain Lithium Levels and Effects on Cognition and Mood in Geriatric Bipolar Disorder: A Lithium-7 Magnetic Resonance Spectroscopy Study. Am J Geriatr Psychiatry;17(1):13-23.
11. Kuzniecky RI. 2004 Clinical applications of MR spectroscopy in epilepsy. Neuroimag Clin N Am;14:507-516.
12. Menuel C, Guillevin R, Costalat R, Perrin M, Sahli-Amor M, Martin-Duverneuil N, Chiras J. 2010 Phosphorus magnetic resonance spectroscopy: Brain pathologies applications. J Neuroradiol;37(2):73-82.
13. Avdievich NT, Hetherington HP. 2007 4 T Actively detuneable double-tuned H-1/P-31 head volume coil and four-channel P-31 phased array for human brain spectroscopy. J Magn Reson;186(2):341-346.
14. de Graaf R. In vivo NMR spectroscopy – Principles and Techniques. In: Sons JW, editor. Chichester, England; 1998. p 64.
15. Mandal PK. 2007 Magnetic resonance spectroscopy (MRS) and its application in Alzheimer's disease.30A(1):40-64.
16. Blenman RAM, Port JD, Felmlee JP. 2007 Selective maximization of P-31 MR spectroscopic signals of in vivo human brain metabolites at 3T. J Magn Reson Imaging;25(3):628-634.
17. Lara RS, Matson GB, Hugg JW, Maudsley AA, Weiner MW. 1993 Quantitation of in vivo phosphorus metabolites in human brain with magnetic-resonance spectroscopic imaging (MRSI). Magn Reson Imaging;11(2):273-278.
18. Buchli R, Duc CO, Martin E, Boesiger P. 1994 Assessment of absolute metabolite concentrations in human tissue by P-31 MRS in-vivo .1. Cerebrum, cerebellum, cerebral gray and white-matter. Magn Reson Med;32(4):447-452.
19. Merboldt KD, Chien D, Hanicke W, Gyngell ML, Bruhn H, Frahm J. 1990 Localized P-31 NMR-spectroscopy of the adult human brain in vivo using stimulated-echo (STEAM) sequences. J Magn Reson;89(2):343-361.
20. Goo HW. 2010 High field strength magnetic resonance imaging in children. Journal of the Korean Medical Association;53(12):1093- 1102.
21. Goodwill PW, Conolly SM. 2010 The XSpace Formulation of the Magnetic Particle Imaging Process: 1-D Signal, Resolution, Bandwidth, SNR, SAR, and Magnetostimulation. IEEE Trans Med Imaging;29(11):1851-1859.
22. Ordidge RJ, Connelly A, Lohman JAB. 1986 Image-selected in vivo spectroscopy (ISIS) - a new technique for spatially selective NMRspectroscopy . J Magn Reson;66(2):283-294.
23. Kegeles LS, Humaran TJ, Mann JJ. 1998 In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry;44(6):382-398.
24. Lawry TJ, Karczmar GS, Weiner MW, Matson GB. 1989 Computer-simulation of MRS localization techniques - an analysis of ISIS. Magnetic Resonance in Medicine;9(3):299-314.
25. Burger C, Buchli R, McKinnon G, Meier D, Boesiger P. 1992 The impact of the ISIS experiment order on spatial contamination. Magn Reson Med;26(2):218-230.
26. Gonen O, Mohebbi A, Stoyanova R, Brown TR. 1997 In vivo phosphorus polarization transfer and decoupling from protons in threedimensional localized nuclear magnetic resonance spectroscopy of human brain. Magn Reson Med;37(2):301-306.
27. Jung WI, Staubert A, Widmaier S, Hoess T, Bunse M, vanErckelens F, Dietze G, Lutz O. 1997 Phosphorus J-coupling constants of ATP in human brain. Magn Reson Med;37(5):802- 804.
28. Arias-Mendoza F, Javaid T, Stoyanova R, Brown TR, Gonen O. 1996 Heteronuclear multivoxel spectroscopy of in vivo human brain: Two-dimensional proton interleaved with three-dimensional H-1-decoupled phosphorus chemical shift imaging. NMR Biomed;9(3):105-113.
29. Potwarka JJ, Drost DJ, Williamson PC, Carr T, Canaran G, Rylett WJ, Neufeld RWJ. 1999 A H-1-decoupled P-31 chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry;45(6):687- 693.
30. Govindaraju V, Young K, Maudsley AA. 2000 Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed;13(3):129-153.
31. Barker PB, Golay X, Artemov D, Ouwerkerk R, Smith MA, Shaka AJ. 2001 Broadband proton decoupling for in vivo brain spectroscopy in humans. Magn Reson Med;45(2):226-232.
32. Wang ZW, Lin JC, Mao WH, Liu WZ, Smith MB, Collins CM. 2007 SAR and temperature: Simulations and comparison to regulatory limits for MRI. J Magn Reson Imaging;26(2):437-441.
33. Collins CM. 2009 Numerical field calculations considering the human subject for engineering and safety assurance in MRI. NMR Biomed;22(9):919-926.
34. Beierbeck H, Martino R, Saunders JK, Benezra C. 1976 Nuclear overhauser effect between phosphorus and hydrogen in selected organo phosphorus-compounds. Can J Chem;54(12):1918-1922.
35. Li CW, Negendank WG, MurphyBoesch J, PadavicShaller K, Brown TR. 1996 Molar quantitation of hepatic metabolites in vivo in proton-decoupled, nuclear Overhauser effect enhanced P-31 NMR spectra localized by three-dimensional chemical shift imaging. NMR Biomed;9(4):141-155.
36. Weber-Fahr W, Bachert P, Henn FA, Braus DF, Ende G. 2003 Signal enhancement through heteronuclear polarisation transfer in in-vivo P-31 MR spectroscopy of the human brain. MAGMA;16(2):68-76.
37. Juchem C, Muller-Bierl B, Schick F, Logothetis NK, Pfeuffer J. 2006 Combined passive and active shimming for in vivo MR spectroscopy at high magnetic fields. J Magn Reson;183(2):278-289.
38. Hetherington HP, Chu WJ, Gonen O, Pan JW. 2006 Robust fully automated shimming of the human brain for high-field H-1 spectroscopic imaging. Magn Reson Med;56(1):26-33.
39. Hetherington HP, Avdievich NI, Kuznetsov AM, Pan JW. 2010 RF Shimming for Spectroscopic Localization in the Human Brain at 7 T. Magn Reson Med;63(1):9-19.
40. Gao Y, Strakowski SM, Reeves SJ, Hetherington HP, Chu WJ, Lee JH. 2006 Fast spectroscopic imaging using online optimal sparse k-space acquisition and projections onto convex sets reconstruction. Magn Reson Med;55(6):1265-1271.
41. Ulrich M, Wokrina T, Ende G, Lang M, Bachert P. 2007 P-31-{H-1} echo-planar spectroscopic imaging of the human brain in vivo. Magn Reson Med;57(4):784-790.
42. Andronesi OC, Ramadan S, Ratai EM, Jennings D, Mountford CE, Sorensen AG. 2010 Spectroscopic imaging with improved gradient modulated constant adiabaticity pulses on high-field clinical scanners. J Magn Reson;203(2):283-293.
43. Menuel C, Guillevin R, Costalat R, Perrin M, Sahli-Amor M, Martin-Duverneuil N, Chiras J. 2010 Phosphorus magnetic resonance spectroscopy: Brain pathologies applications. J Neuroradiol;37(2):73-82.
44. Boyer PD. 1999 Molecular motors - What makes ATP synthase spin? Nature;402(6759):247-+.
45. Du F, Zhu XH, Zhang Y, Friedman M, Zhang NY, Ugurbil K, Chen W. 2008 Tightly coupled brain activity and cerebral ATP metabolic rate. Proc Natl Acad Sci U S A;105(17):6409-6414.
46. Chaumeil MM, Valette J, Guillermier M, Brouillet E, Boumezbeur F, Herard AS, Bloch G, Hantraye P, Lebon V. 2009 Multimodal neuroimaging provides a highly consistent picture of energy metabolism, validating P-31 MRS for measuring brain ATP synthesis. Proc Natl Acad Sci U S A;106(10):3988-3993.
47. Wu RH, Poublanc J, Mandell D, Detzler G, Crawley A, Qiu QC, terBrugge K, Mikulis DJ, Ieee. Evidence of brain mitochondrial activities after oxygen inhalation by P-31 magnetic resonance spectroscopy at 3T. 2007 In: 2007 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vols 1-16., p 2899-2902.
48. Komoroski RA, Pearce JM, Mrak RE. 2008 P- 31 NMR Spectroscopy of phospholipid metabolites in postmortem schizophrenic brain. Magn Reson Med;59(3):469-474.
49. Puri B, Treasaden I. 2009 A human in vivo study of the extent to which 31-phosphorus neurospectroscopy phosphomonoesters index cerebral cell membrane phospholipid anabolism. Prostaglandins Leukot Essent Fatty Acids;81(5-6):307-8.
50. Alberts B, Johnson A, Lewis J. Molecular Biology of the Cell. Science G, editor. New York; 2002.
51. Farooqui AA, Hirashima Y, Horrocks LA. Brain phospholipases and their role in signal transduction. In: Bazan NG, Murphy MG, Taffano G, editors. Neurobiology of Essential Fatty Acids. Volume 318, Advances in Experimental Medicine and Biology. New York: Plenum Press Div Plenum Publishing Corp; 1992. p 11-25.
52. Horrobin DF. 1998 The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res;30(3):193-208.
53. Shioiri T, Hamakawa H, Kato T, Fujii K, Murashita J, Inubushi T, Someya T. 2000 Frontal lobe membrane phospholipid metabolism and ventricle to brain ratio in schizophrenia: preliminary P-31-MRS and CT studies. Eur Arch Psychiatry Clin Neurosci;250(4):169-174.
54. Rapoport S. 2001 In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci;16:243-261.
55. Barker PB, Butterworth EJ, Boska MD, Nelson J, Welch KMA. 1999 Magnesium and pH imaging of the human brain at 3.0 Tesla. Magn Reson Med;41(2):400-406.
56. Petroff OAC, Prichard JW, Behar KL, Alger JR, Denhollander JA, Shulman RG. 1985 Cerebral intracellular ph by P-31 nuclear magnetic-resonance spectroscopy. Neurology;35(6):781-788.
57. Berg J, Tymoczko J, Stryer L. Biochemistry. Freeman WH, editor. New York; 2002.
58. Lodish H, Berk A, Zipursky S. Molecular Cell Biology. Freeman WH, editor. New York; 2000.
59. Xiong ZG, Chu XP, Simon RP. 2006 Ca2+- permeable acid-sensing ion channels and ischemic brain injury. J Membr Biol;209(1):59-68.
60. Petroff EY, Price MP, Snitsarev V, Gong H, Korovkina V, Abboud FM, Welsh MJ. 2008 Acid-sensing ion channels interact with and inhibit BKK+ channels. Proc Natl Acad Sci U S A;105(8):3140-3144.
61. Chesler M. 2003 Regulation and modulation of pH in the brain. Physiol Rev;83(4):1183- 1221.
62. Yermolaieva O, Leonard AS, Schnizier MK, Abboud FM, Welsh MJ. 2004 Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. Proc Natl Acad Sci U S A;101(17):6752-6757.
63. Iotti S, Frassineti C, Alderighi L, Sabatini A, Vacca A, Barbiroli B. 1996 In vivo assessment of free magnesium concentration in human brain by P-31 MRS. A new calibration curve based on a mathematical algorithm. NMR Biomed;9(1):24-32.
64. Halvorson HR, Vandelinde AMQ, Helpern JA, Welch KMA. 1992 Assessment of magnesium concentrations by P-31 NMR invivo. NMR Biomed;5(2):53-58.
65. Aussedat J, Lortet S, Ray A, Rossi A, Heckman M, Zimmer HG, Vincent M, Sassart J. 1992 Energy metabolism of the hypertrophied heart studied by 31P nuclear magnetic resonance. Cardioscience;3(4):233- 239.
66. Marseilles M, Eicher JC, Gomez MC, Cottin Y, Cohen M, Walker P. 1996 Improvement of skeletal muscle oxidative metabolism after heart transplantation in heart failure patients. A 31P NMR study. Sci Sports;11(1):28-33.
67. Bowers JL, Lanir A, Metz KR, Kruskal JB, Lee RGL, Balschi J, Federman M, Khettry U, Clouse ME. 1992 NA-23-NMR and 31P-NMR studies of perfused mouse-liver during nitrogen hypoxia. Am J Physiol;262(4):G636- G644.
68. Zakian KL, Koutcher JA, Malhotra S, Thaler H, Jarnagin W, Schwartz L, Fong YM. 2005 Liver regeneration in humans is characterized by significant changes in cellular phosphorus metabolism: Assessment using protondecoupled P-31- magnetic resonance spectroscopic imaging. Magn Reson Med;54(2):264-271.
69. Sharma R, Sinha S, Danishad KA, Vikram NK, Gupta A, Ahuja V, Jagannathan NR, Pandey RM, Misra A. 2009 Investigation of hepatic gluconeogenesis pathway in nondiabetic Asian Indians with non-alcoholic fatty liver disease using in vivo (P-31) phosphorus magnetic resonance spectroscopy. Atherosclerosis;203(1):291-297.
70. Kemp GJ, Meyerspeer M, Moser E. 2007 Absolute quantification of phosphorus metabolite concentrations in human muscle in vivo by P-31 MRS: a quantitative review. NMR Biomed;20(6):555-565.
71. van Elderen SGC, Doornbos J, van Essen EHR, Lemkes H, Maassen JA, Smit JWA, de Roos A. 2009 Phosphorus-31 Magnetic Resonance Spectroscopy of Skeletal Muscle in Maternally Inherited Diabetes and Deafness A3243G Mitochondrial Mutation Carriers. J Magn Reson Imaging;29(1):127-131.
72. Lim EL, Hollingsworth KG, Thelwall PE, Taylor R. 2010 Measuring the acute effect of insulin infusion on ATP turnover rate in human skeletal muscle using phosphorus-31 magnetic resonance saturation transfer spectroscopy. NMR Biomed;23(8):952-957.
73. Holtzman D, Mulkern R, Tsuji M, Cook C, Meyers R. 1996 Phosphocreatine and creatine kinase in piglet cerebral gray and white matter in situ. Dev Neurosci;18(5-6):535-541.
74. Holtzman D, Mulkern R, Meyers R, Cook C, Allred E, Khait I, Jensen F, Tsuji M, Laussen P. 1998 In vivo phosphocreatine and ATP in piglet cerebral gray and white matter during seizures. Brain Res;783(1):19-27.
75. Bischof MG, Mlynarik V, Brehm A, Bernroider E, Krssak M, Bauer E, Madl C, Bayerle-Eder M, Waldhausl W, Roden M. 2004 Brain energy metabolism during hypoglycaemia in healthy and Type 1 diabetic subjects. Diabetologia;47(4):648-651.
76. Mason GF, Chu WJ, Vaughan JT, Ponder SL, Twieg DB, Adams D, Hetherington HP. 1998 Evaluation of P-31 metabolite differences in human cerebral gray and white matter. Magn Reson Med;39(3):346-353.
77. Hetherington HP, Spencer DD, Vaughan JT, Pan JW. 2001 Quantitative P-31 spectroscopic imaging of human brain at 4 tesla: Assessment of gray and white matter differences of phosphocreatine and ATP. Magnetic Resonance in Medicine;45(1):46-52.
78. Buchli R, Martin E, Boesiger P, Rumpel H. 1994 Developmental changes of phosphorus metabolite concentrations in the human brain - a P-31 magnetic resonance spectroscopy study in vivo. Pediatric Research;35(4):431-435.
79. Doyle VL, Payne GS, Collins DJ, Verrill MW, Leach MO. 1997 Quantification of phosphorus metabolites in human calf muscle and softtissue tumours from localized MR spectra acquired using surface coils. Physics in Medicine and Biology;42(4):691-706.
80. Bertoni-Freddari C, Fattoretti P, Giorgetti B, Solazzi M, Balietti M, Di Stefano G, Casoli T. Decay of mitochondrial metabolic competence in the aging cerebellum. In: DeGrey ADN, editor. Strategies for Engineered Negligible Senescence: Why Genuine Control of Aging May Be Foreseeable. Volume 1019, Annals of the New York Academy of Sciences; 2004. p 29-32.
81. Bertoni-Freddari C, Fattoretti P, Giorgetti B, Solazzi M, Balietti M, Meier-Ruge W. 2004 Role of mitochondrial deterioration in physiological and pathological brain aging. Gerontology;50(3):187-192.
82. Schapira AHV. 2006 Mitochondrial disease. Lancet;368(9529):70-82.
83. Murashita J, Kato T, Shioiri T, Inubushi T, Kato N. 1999 Age-dependent alteration of metabolic response to photic stimulation in the human brain measured by P-31 MRspectroscopy. Brain Res;818(1):72-76.
84. Rae C, Scott RB, Lee M, Simpson JM, Hines N, Paul C, Anderson M, Karmiloff-Smith A, Styles P, Raddac GK. 2003 Brain bioenergetics and cognitive ability. Dev Neurosci;25(5):324-331.
85. Forester B, Berlow Y, Harper D, Jensen J, Lange N, Froimowitz M, Ravichandran C, Iosifescu D, Lukas S, Renshaw P and others. 2010 Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed;23(3):242-50.
86. Kadota T, Horinouchi T, Kuroda C. 2001 Development and aging of the cerebrum: Assessment with proton MR spectroscopy. Am J Neuroradiol;22(1):128-135.
87. Moreno-Torres A, Pujol J, Soriano-Mas C, Deus J, Iranzo A, Santamaria J. 2005 Agerelated metabolic changes in the upper brainstem tegmentum by MR spectroscopy. Neurobiol Aging;26(7):1051-1059.
88. Husted CA, Matson GB, Adams DA, Goodin DS, Weiner MW. 1994 In vivo detection of myelin phospholipids in multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging. Ann Neurol;36(2):239- 241.
89. Steen C, Koch M, Mostert J, De Keyser J. 2008 Phosphorus spectroscopy of normalappearing white matter in multiple sclerosis. Mult Scler;14:S222-S222.
90. Laptook AR, Corbett RJT, Uauy R, Mize C, Mendelsohn D, Nunnally RL. 1989 Use of P- 31 magnetic-resonance spectroscopy to characterize evolving brain-damage after perinatal asphyxia. Neurology;39(5):709-712.
91. Levine SR, Helpern JA, Welch KM, Vande Linde AM, Sawaya KL, Brown EE, Ramadan NM, Deveshwar RK, Ordidge RJ. 1992 Human focal cerebral ischemia: evaluation of brain pH and energy metabolism with P-31 NMR spectroscopy. Radiology;185(2):537-44.
92. Helpern JA, Vande Linde AM, Welch KM, Levine SR, Schultz LR, Ordidge RJ, Halvorson HR, Hugg JW. 1993 Acute elevation and recovery of intracellular [Mg2+] following human focal cerebral ischemia. Neurology;43(8):1577-81.
93. Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KM. 1989 Low brain magnesium in migraine. Headache;29(9):590-3.
94. Lodi R, Lotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V, Soriani S, Montagna P, Barbiroli B. 2001 Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull;54(4):437-441.
95. Boska MD, Welch KMA, Barker PB, Nelson JA, Schultz L. 2002 Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology;58(8):1227-1233.
96. Barbiroli B, Martinelli P, Patuelli A, Lodi R, Iotti S, Cortelli P, Montagna P. 1999 Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. Mov Disord;14(3):430-435.
97. Hoang TQ, Dubowitz DJ, Moats R, Kopyov O, Jacques D, Ross BD. 1998 Quantitative proton-decoupled P-31 MRS and H-1 MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology;50(4):1033-1040.
98. Smith CD, Gallenstein LG, Layton WJ, Kryscio RJ, Markesbery WR. 1993 P-31 magnetic-resonance spectroscopy in Alzheimer's and Pick's disease. Neurobiol Aging;14(1):85-92.
99. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. 2001 Brain membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research;26(7):771- 782.
100. Forlenza OV, Wacker P, Nunes PV, Yacubian J, Castro CC, Otaduy MCG, Gattaz WF. 2005 Reduced phospholipid breakdown in Alzheimer's brains: a P-31 spectroscopy study. Psychopharmacology;180(2):359-365.
101. Heindel W, Bunke J, Glathe S, Steinbrich W, Mollevanger L. 1988 Combined H-1-MR imaging and localized P-31-spectroscopy of intracranial tumors in 43 patients. J Comput Assist Tomogr;12(6):907-916.
102. Heindel W, Friedmann G. 1988 Imageguided localized P-31 NMR-spectroscopy in brain tumors. Tumordiagnostik and Therapie;9(4):166-166.
103. Hubesch B, Sappeymarinier D, Roth K, Meyerhoff DJ, Matson GB, Weiner MW. 1990 P-31 MR spectroscopy of normal human brain and brain tumors. Radiology;174(2):401-409.
104. Arnold DL, Emrich JF, Shoubridge EA, Villemure JG, Feindel W. 1991 Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy. J Neurosurg;74(3):447-53.
105. Maintz D, Heindel W, Kugel H, Jaeger R, Lackner KJ. 2002 Phosphorus-31 MR spectroscopy of normal adult human brain and brain tumours. NMR Biomed;15(1):18-27.
106. Keshavan MS, Stanley JA, Montrose DM, Minshew NJ, Pettegrew JW. 2003 Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo P-31 MRS study. Mol Psychiatry;8(3):316-323.
107. Rzanny R, Klemm S, Reichenbach JR, Pfleiderer SOR, Schmidt B, Volz HP, Blanz B, Kaiser WA. 2003 31P-MR spectroscopy in children and adolescents with a familial risk of schizophrenia. Eur Radiol;13(4):763-770.
108. Jensen JE, Miller J, Williamson PC, Neufeld RWJ, Menon RS, Malla A, Manchanda R, Schaefer B, Densmore M, Drost DJ. 2006 Grey and white matter differences in brain energy metabolism in first episode schizophrenia: P-31-MRS chemical shift imaging at 4 Tesla. Psychiatry Res;146(2):127-135.
109. Smesny S, Rosburg T, Nenadic I, Fenk KP, Kunstmann S, Rzanny R, Volz HP, Sauer H. 2007 Metabolic mapping using 2D P-31-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage;35(2):729-737.
110. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Pettegrew JW, Keshavan MS, Bukstein OG. 2006 Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo P-31 spectroscopy study. Psychiatry Res;148(2-3):217-221.
111. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Keshavan MS, Bukstein OG, Pettegrew JW. 2008 Evidence of Developmental Alterations in Cortical and Subcortical Regions of Children With Attention-Deficit/Hyperactivity Disorder A Multivoxel In Vivo Phosphorus 31 Spectroscopy Study. Arch Gen Psychiatry;65(12):1419-1428.
112. Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K, McClure RJ. 2002 P-31-MRS study of acetylL-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord;4(1):61-66.
113. Hamakawa H, Murashita J, Yamada N, Inubushi T, Kato N, Kato T. 2004 Reduced intracellular pH in the basal ganglia and whole brain measured by P-31-MRS in bipolar disorder. Psychiatry Clin Neurosci;58(1):82- 88.
114. Laxer KD, Hubesch B, Sappey-Marinier D, Weiner MW. 1992 Increased pH and inorganic phosphate in temporal seizure foci demonstrated by [31P]MRS. Epilepsia;33(4):618-23.
115. der Grond J, Gerson J, Laxer K, Hugg J, Matson G, Weiner M. 1998 Regional Distribution of Interictal 'P Metabolic Changes in Patients with Temporal Lobe Epilepsy. Epilepsia;39(5):527-536.
116. Chu WJ, Hetherington HP, Kuzniecky RI, Vaughan JT, Twieg DB, Faught RE, Gilliam FG, Hugg JW, Elgavish GA. 1996 Is the intracellular pH different from normal in the epileptic focus of patients with temporal lobe epilepsy? A 31P-NMR study. Neurology;47:756-760.
117. Chu WJ, Hetherington HP, Kuzniecky RI, Simor T, Mason GF, Elgavish GA. 1998 Lateralization of human temporal lobe epilepsy by 31P NMR spectroscopic imaging at 4,1T. Neurology;51:472-479.
118. Hetherington HP, Kim JH, Pan JW, Spencer DD. 2004 H-1 and P-31 spectroscopic imaging of epilepsy: Spectroscopic and histologic correlations. Epilepsia;45:17-23.
119. Simor T, Chu WJ, Hetherington H, Kuzniecky R, Elgavish G. Tailored temporal lobectomy induced improvements in 4.1T 31PNMR SI generated phosphorous metabolite indices in temporal lobe epilepsy. 1997; Vancouver, Canada. p 33.
120. Pan JW, Bebin EM, Chu WJ, Hetherington HP. 1999 Ketosis and epilepsy: P-31 spectroscopic imaging at 4.1 T. Epilepsia;40(6):703-707.
121. Hetherington HP, Pan JW, Spencer DD. 2002 H-1 and P-31 spectroscopy and bioenergetics in the lateralization of seizures in temporal lobe epilepsy. J Magn Reson Imaging;16(4):477-483.
122. Andrade CS, Otaduy MCG, Valente KDR, Maia DF, Park EJ, Valerio RMF, Tsunemi MH, Leite CC. 2011 Phosphorus magnetic
|